We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
-4.76%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
+$203M
Cap. Flow
+$295M
Cap. Flow %
27.94%
Top 10 Hldgs %
61.48%
Holding
30
New
7
Increased
14
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$47M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46.8M
3
ONC
BeOne Medicines Ltd
ONC
+$44.1M
4
ARGX icon
argenx
ARGX
+$33.9M
5
INCY icon
Incyte
INCY
+$32M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$54.3M
2
AKRO
Akero Therapeutics
AKRO
+$33.1M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$20.9M
4
ARVN icon
Arvinas
ARVN
+$20.5M
5
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$8.17M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
– –
-604,544
Closed -$33.1M
ARVN icon
27
Arvinas
ARVN
$549M
– –
-599,599
Closed -$20.5M
PRTA icon
28
Prothena Corp
PRTA
$446M
– –
-75,000
Closed -$4.52M
KRTX
29
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-106,210
Closed -$20.9M
HZNP
30
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-477,585
Closed -$54.3M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Paradigm Biocapital Advisors held 30 positions worth $1.06B, up 24% from $852M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Paradigm Biocapital Advisors deployed $295M of net new capital in Q1 2023, opening 7 new positions and adding to 14 existing holdings. Its largest new stake was Keros Therapeutics: 930,752 shares worth $39.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Poseida Therapeutics, Inc. Common Stock, an estimated $8.17M trimmed.

  • Paradigm Biocapital Advisors's largest Q1 2023 buy was Keros Therapeutics: 930,752 shares worth $39.7M.
  • Paradigm Biocapital Advisors added most to argenx in Q1 2023, an estimated $33.9M increase.
  • Paradigm Biocapital Advisors's biggest Q1 2023 reduction was Poseida Therapeutics, Inc. Common Stock, cutting an estimated $8.17M.
  • Paradigm Biocapital Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $54.3M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 61% of its $1.06B portfolio in Q1 2023.
  • Paradigm Biocapital Advisors opened 7 new positions and closed 5 in Q1 2023.
  • Paradigm Biocapital Advisors's portfolio value rose 24% quarter-over-quarter to $1.06B.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2023, filed 15 May 2023.